Glenmark Pharmaceuticals receives ANDA approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg

  • Posted on: 7 January 2020
  • By: PharmaTutor News

Pharma Admission

Pharma courses

pharma admission

pharma courses

 

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S.FDA) for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, the generic version of Exjade®1 Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, of Novartis Pharmaceuticals Corporation.

According to IQVIATM sales data for the 12‐month period ending November 2019, the Exjade® Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg market2 achieved annual sales of approximately $106.4 million*.

Glenmark’s current portfolio consists of 165 products authorized  for  distribution  in  the  U.S. marketplace and 43 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email


Latest News